ID   PR-GTL-16
AC   CVCL_7696
DR   cancercelllines; CVCL_7696
DR   Wikidata; Q54947819
RX   PubMed=21208906;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:90197; PHA-665752.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
DI   NCIt; C4004; Gastric adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_7668 ! GTL-16
SX   Female
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 18
RX   PubMed=21208906; DOI=10.1158/1078-0432.CCR-10-0253;
RA   Bachleitner-Hofmann T., Sun M.Y., Chen C.-T., Liska D., Zeng Z.-S.,
RA   Viale A.J., Olshen A.B., Mittlbock M., Christensen J.G., Rosen N.,
RA   Solit D.B., Weiser M.R.;
RT   "Antitumor activity of SNX-2112, a synthetic heat shock protein-90
RT   inhibitor, in MET-amplified tumor cells with or without resistance to
RT   selective MET Inhibition.";
RL   Clin. Cancer Res. 17:122-133(2011).